- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Abdominal Subcutaneous Fat Thickness and Glucose Challenge Test may predict Gestational Diabetes claims study
Gestational diabetes mellitus (GDM) refers to the occurrence of diabetes or impaired carbohydrate intolerance during the second or third trimester of pregnancy, and it does not include pre-existing type 1 or type 2 diabetes. Recent study investigated the combined use of abdominal subcutaneous fat thickness (ASFT) and a 50-g glucose challenge test (GCT) in the second trimester to predict the development of gestational diabetes mellitus (GDM). The study involved 728 pregnant women, and the results suggest that this combined approach had high sensitivity and specificity in predicting GDM cases.
Maternal obesity is strongly linked with adverse perinatal and maternal outcomes, including insulin resistance, GDM, and metabolic syndrome. However, the prevalence of GDM shows significant differences among pregnant women with obesity. Ultrasonography is a useful tool to assess the amount of maternal central fat throughout gestation. Previous studies by the authors found that an increased ASFT (>18.1 mm) was highly associated with the subsequent development of GDM.
In this study, all pregnant women underwent ASFT measurement and a 50-g GCT between 24-28 weeks of gestation. Even if the 50-g GCT was normal, 100-g oral glucose tolerance test (OGTT) was offered to patients with an ASFT value above 18.1 mm. Among the 728 women, 154 (21.2%) were screened positive on the 50-g GCT, and 43 (5.9%) were eventually diagnosed with GDM after the 100-g OGTT. In total, 67 (9.2%) had an ASFT measurement above 18.1 mm.
The key findings are that a 50-g GCT combined with ASFT measurement above 18.1 mm predicted GDM with a sensitivity of 87.9%, a specificity of 88.7%, a positive predictive value (PPV) of 36.0%, and a negative predictive value (NPV) of 99.7%. This suggests that this combined approach during routine antenatal care in the second trimester could be a beneficial indicator for predicting GDM cases.
The authors conclude that ASFT measurement is anticipated to be extensively used as an indicative variable for predicting GDM cases during the second trimester of pregnancy. This simple, non-invasive measurement could help identify pregnant women at higher risk of GDM who may benefit from early testing and intervention, potentially improving maternal and fetal outcomes.
Key Points -
Here are the 6 key points from the research paper:
1. The study investigated the combined use of abdominal subcutaneous fat thickness (ASFT) and a 50-g glucose challenge test (GCT) in the second trimester to predict the development of gestational diabetes mellitus (GDM) in 728 pregnant women.
2. Previous studies by the authors found that an increased ASFT (>18.1 mm) was highly associated with the subsequent development of GDM.
3. In this study, all pregnant women underwent ASFT measurement and a 50-g GCT between 24-28 weeks of gestation. Women with an ASFT value above 18.1 mm underwent a 100-g oral glucose tolerance test (OGTT) even if the 50-g GCT was normal.
4. The key finding was that the combination of a 50-g GCT and ASFT measurement above 18.1 mm predicted GDM with a sensitivity of 87.9%, a specificity of 88.7%, a positive predictive value (PPV) of 36.0%, and a negative predictive value (NPV) of 99.7%.
5. The authors conclude that ASFT measurement is anticipated to be extensively used as an indicative variable for predicting GDM cases during the second trimester of pregnancy.
6. This simple, non-invasive measurement could help identify pregnant women at higher risk of GDM who may benefit from early testing and intervention, potentially improving maternal and fetal outcomes.
Reference –
Süleyman Cemil Oğlak, Emine Zeynep Yılmaz & Mehmet Şükrü Budak (2024) Abdominal subcutaneous fat thickness combined with a 50-g glucose challenge test at 24-28 weeks of pregnancy in predicting gestational diabetes mellitus, Journal of Obstetrics and Gynaecology, 44:1, 2329880, DOI: 10.1080/01443615.2024.2329880
MBBS, MD (Anaesthesiology), FNB (Cardiac Anaesthesiology)
Dr Monish Raut is a practicing Cardiac Anesthesiologist. He completed his MBBS at Government Medical College, Nagpur, and pursued his MD in Anesthesiology at BJ Medical College, Pune. Further specializing in Cardiac Anesthesiology, Dr Raut earned his FNB in Cardiac Anesthesiology from Sir Ganga Ram Hospital, Delhi.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751